Business
CORRECTION FROM SOURCE: Theralase to Present Groundbreaking Research at ASTRO 2025
Radiation-Activated Rutherrin(R) Versus Radiation Alone in Preclinical Cancer Models to be Presen...
About this update from Theralase Technologies Inc.
[{"type":"text","content":"CORRECTION FROM SOURCE: Theralase to Present Groundbreaking Research at ASTRO 2025Radiation-Activated Rutherrin(R) Versus Radiation Alone in Preclinical Cancer Models to be Presented at ASTRO 2025This Press Release removes references to preclinical data that has not yet been presented.Toronto, Ontario--(Newsfile Corp. - May 29, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (\"Theralase®\" or the \"Company\"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses will present promising new preclinical results at the 2025 American Society for Radiation Oncology (\"ASTRO\") 67th Annual Meeting. The Company's latest research evaluates radiation-activated Rutherrin® versus radiation alone in the destruction of cancer cells in a number of preclinical cancer models.This data will be showcased at the 2025 ASTRO 67th Annual Meeting, the world's largest gathering of radiation oncology professionals, taking place in late September in San Francisco, California. ASTRO has selected the Theralase® abstract titled, \"Rutherrin® Activated by Radiation Therapy Evaluated for Synergistic Tumor Regression through Direct Destruction and Immune Activation in Multiple Preclinical Cancer Models\", for presentation in a scientific poster session. The study explores the potent anti-cancer effects of Rutherrin®—a ruthenium-based small molecule drug formulated with recombinant human transferrin for intravenous administration. Once activated by ionizing radiation through a process known as Radio Dynamic Therapy (\"RDT\"), Rutherrin® initiates a two-phase cancer-killing response: the generation of Reactive Oxygen Species (\"ROS\") for immediate cytotoxicity, followed by Immunogenic Cell Death (\"ICD\") to stimulate a durable immune response.The Preclinical Data Presented Will Evaluate:Selective Tumor Targeting: Rutherrin®'s accumulation in tumor tissues versus healthy cells.Blood-Brain Barrier Penetration: Concentrations in Glio Blastoma Multiforme (\"GBM\") tumors versus healthy brain tissue.Synergistic Mechanism: Combination of direct tumor cell destruction with immune activation.Survival Rates: Survival benefits compared to radiation therapy alone.Resistance: Inhibition of mechanis...